Number of words in Number of words in Introduction -798 Abcb1 and Abcg2. We analyzed the effect of halving the efflux activity of these transporters at the blood-brain barrier (BBB) by generating heterozygous Abcb1a/1b;Abcg2 knockout mice, and testing plasma and brain levels of the drugs after oral administration at 10 mg/kg. RT-PCR analysis confirmed ~2-fold decreased expression of both transporters in brain. Interestingly, whereas complete knockout of the transporters caused 24-to 36-fold increases in brain accumulation of the drugs, the heterozygous mice only displayed 1.6-to 1.9-fold increases of brain accumulation relative to wild-type mice. These results are well in line with the predictions of the pharmacokinetic models, and provide strong support for their validity for a wider range of drugs. Moreover, retrospective analysis of fetal accumulation of drugs across the placenta in Abcb1a/1b heterozygous knockout pups suggests that these models equally apply to the maternal-fetal barrier.
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Introduction Dasatinib, sorafenib and sunitinib are orally active, small-molecule multi-targeted tyrosine kinase inhibitors (TKIs) used for the treatment of cancer. Dasatinib (Sprycel; BMS-354825), a potent second generation BCR-ABL kinase inhibitor (Lombardo et al., 2004) , used as first-line treatment for adult patients newly diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (Kantarjian et al., 2010) . Sorafenib (Nexavar, BAY43-9006), a Raf kinase and vascular endothelial growth factor receptor inhibitor, is currently used for the treatment of patients with unresectable hepatocellular carcinoma and advanced renal cell carcinoma (Escudier et al., 2007; Llovet et al., 2008) . Sunitinib (Sutent, SU11248) is a receptor tyrosine kinase inhibitor that is used in the therapy of progressive, well-differentiated pancreatic neuroendocrine tumors, metastatic renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor Raymond et al., 2011; Rock et al., 2007) .
ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp; ABCB1) and breast cancer resistance protein (BCRP; ABCG2) are highly expressed in small intestinal epithelium and at the blood-brain barrier (BBB), where they can limit the oral availability, but especially the brain accumulation of many clinically used TKIs (see also Supplemental Figure 1 ) (Agarwal et al., 2010; Chen et al., 2009; Durmus et al., 2012; Lagas et al., 2009; Lagas et al., 2010; Mittapalli et al., 2012; Polli et al., 2009; Tang et al., 2012) . There is considerable overlap in the substrate specificity between Abcb1 and Abcg2, and many TKIs, including dasatinib, sorafenib, and sunitinib, are dual substrates of these transporters (Agarwal et al., 2010; Chen et al., 2009; Lagas et al., 2009; Lagas et al., 2010; Tang et al., 2012) . Dasatinib, sorafenib, and sunitinib can be classified into three different groups based on their known in vivo characteristics with regard to brain accumulation profiles (Supplemental Figure 1) . For instance, brain accumulation of dasatinib is mainly restricted by Abcb1, whereas Abcg2 plays a more important role in limiting brain accumulation of sorafenib. For sunitinib, Abcb1 and Abcg2 contribute equally to its restricted brain accumulation. With respect to oral availability, dasatinib is primarily
restricted by Abcb1, whereas plasma pharmacokinetics of sorafenib and sunitinib are not affected by Abcb1 and/or Abcg2.
A striking finding from brain accumulation studies with shared Abcb1 and Abcg2 substrates is that the single disruption of Abcb1a/1b or Abcg2 in mice often has little or no detectable effect on brain accumulation, whereas simultaneous disruption of these two transporters results in a dramatic increase of brain accumulation of many TKIs (see also Supplemental Figure 1 ) (Agarwal et al., 2010; Chen et al., 2009; Kodaira et al., 2010; Lagas et al., 2009; Lagas et al., 2010; Polli et al., 2009; Tang et al., 2012; Zhou et al., 2009 ). These findings have prompted researchers to envisage a synergistic or cooperative role of ABCB1 and ABCG2 in the efflux of dual substrates at the BBB. However, Kodaira et al. (2010) applied a relatively simple pharmacokinetic model that describes that the disproportionate effect of simultaneous removal of both transporters can simply result from the fact that the intrinsic efflux transport activities at the BBB of Abcb1 and Abcg2 are each considerably larger than the remaining (passive, or lowly active) efflux activity at the BBB. Therefore, the seemingly synergistic effect of the removal of both Abcb1 and Abcg2 on the accumulation of their shared substrates in the brain can be explained by their separate contributions to the net efflux at the BBB, without postulating any direct or indirect interaction between Abcb1 and Abcg2. Interestingly, similar predictions are made by the more sophisticated pharmacokinetic models developed by Kalvass and Pollack (2007) and Zamek-Gliszczynski et al. (2009) , which aimed to resolve complications with describing transepithelial active transport as for instance identified by Bentz et al. (2005) .
Each of these theoretical models also predicts that halving the amount of active transporter-mediated drug efflux activity at the BBB should result in only a minor increase of drug accumulation into the brain (never more than 2-fold), even if complete removal of the active transporter-mediated efflux results in a very large increase in brain accumulation. In order to test these predictions, we aimed to analyze the effect of halving the active efflux transporter activity at the BBB by using wild-type, heterozygous Abcb1a/1b(+/-);Abcg2(+/-) and homozygous Abcb1a/1b(-/-);Abcg2(-/-) mice, with 2, 1, and 0 active gene copies of each of the active transporters, respectively, and study the effect on TKI brain accumulation. We chose dasatinib, This article has not been copyedited and formatted. The final version may differ from this version. This functional diversity makes it more likely that consistent results obtained for these three drugs can be extrapolated to a much wider range of drugs affected by Abcb1 and Abcg2.
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Materials and Methods
Chemicals and reagents
Dasatinib, sorafenib and sunitinib were purchased from Sequoia Research Products (Pangbourne, UK). Heparin (5000 IU/ml) was obtained from Leo Pharma BV (Breda, The Netherlands). Lithiumheparinized microvettes and dipotassium-EDTA microvettes were obtained from Sarstedt (Numbrecht, Germany). EDTA disodium salt pH 8.0 was from Cambrex BioScience Inc.
(Rockland, ME). Bovine serum albumin (BSA), fraction V, was purchased from Roche (Mannheim, Germany). Isoflurane (Forane) was from Abbott Laboratories (Queenborough, Kent, UK). All other chemicals and reagents were obtained from Sigma-Aldrich (Steinheim, Germany).
Animals
Mice were housed and handled according to institutional guidelines complying with Dutch legislation. Male wild-type, Abcb1a/1b(+/-);Abcg2(+/-) and Abcb1a/1b(-/-);Abcg2(-/-) (Jonker et al., 2005) mice, all of a >99% FVB genetic background, were used between 8 and 14 weeks of age.
Animals were kept in a temperature-controlled environment with a 12-hr light/12-hr dark cycle and received a standard diet (AM-II, Hope Farms B.V., Woerden, The Netherlands) and acidified water ad libitum. Abcb1a/1b(+/-);Abcg2(+/-) mice were the F1 of a cross between FVB wild-type and Abcb1a/1b(-/-);Abcg2(-/-) mice.
Drug solutions
Dasatinib was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 25 mg/ml and 25-fold diluted with 50 mM sodium acetate buffer (pH 4.6) to obtain a concentration of 1 mg/ml. Sorafenib tosylate was dissolved in DMSO (25 mg/ml) and 25-fold diluted with Cremophor EL/ethanol/water (1:1:6, v/v/v). Sunitinib malate was dissolved in DMSO at a concentration of 25 mg/ml and further diluted with 50 mM sodium acetate buffer (pH 4.6) to yield a concentration of 1 mg/ml. Dasatinib, sorafenib and sunitinib were administered orally at 10 mg/kg body weight (10 ml/kg).
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Plasma pharmacokinetics and relative brain accumulation of TKIs in mice
To minimize variation in absorption upon oral administration, mice were fasted for 3 hr before dasatinib, sorafenib or sunitinib were administered by gavage into the stomach, using a bluntended needle. To prevent blood from coagulating, heparin was used for the dasatinib and sunitinib pharmacokinetic experiments, whereas EDTA was used for the sorafenib pharmacokinetic experiment. Tail vein blood sampling was performed at 0.25, 0.5, 1, 2 and 4 hr time-points after oral administration, using either microvettes containing dipotassium-EDTA or lithium heparin. Six hours after oral administration, mice were anesthetized with isoflurane and blood was collected by cardiac puncture, in which 0.5 M disodium-EDTA or 5000 IU/ml heparin were used as anticoagulants. Immediately thereafter, mice were sacrificed by cervical dislocation and brains were rapidly removed. Plasma was isolated from the blood by centrifugation at 2,100 g 
Drug analyses
Dasatinib, sorafenib and sunitinib concentrations in plasma and brain homogenates were analyzed by liquid chromatography coupled to tandem mass spectrometry as described previously (Lagas et al., 2009; Sparidans et al., 2009; Tang et al., 2012, respectively) . Lower limit of quantification (LLQ) values for dasatinib and sunitinib were 5 ng/ml and 15.6 ng/g for the plasma and brain homogenates, respectively. LLQ values for sorafenib were 10 ng/ml and 31.2 ng/g for the plasma and brain homogenates, respectively.
RNA isolation, cDNA synthesis and real-time RT-PCR
RNA isolation from mouse brain and small intestine and subsequent cDNA synthesis and RT-PCR were performed as described (Lagas et al., 2012) . To circumvent detection of non-functional This article has not been copyedited and formatted. The final version may differ from this version.
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RNA which is transcribed from the Abcb1a and Abcg2 knockout alleles (Schinkel et al., 1994 and data not shown), we used RT-PCR probes positioned within the deleted exons of both genes. 
Statistical analysis
Pharmacokinetic parameters were calculated by non-compartmental methods using the software package PK Solutions 2.0.2 (Summit Research Services, Ashland, OH). The area under the plasma concentration-time curve was calculated using the trapezoidal rule, without extrapolating to infinity. The maximum drug concentration in plasma (C max ) and the time to reach maximum drug concentration in plasma (T max ) were determined directly from mean concentration-time data.
Data are presented as means ± SD. For parametric statistical analysis, all the data except for plasma concentrations and AUC 0-6hr values were log-transformed to obtain equality in variances.
One-way analysis of variance (ANOVA) was used to determine statistical significance of differences between groups, after which post-hoc tests with Bonferroni correction were performed for comparison between individual groups. Differences were considered statistically significant when P < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. knockout alleles (Schinkel et al., 1994 ) (data not shown), we used RT-PCR probes positioned within the deleted exons of both genes. We expected that the expression levels of wild-type
Abcb1a and Abcg2 alleles in the small intestine and brain of heterozygous mice would be about half of the expression levels observed in wild-type mice. However, the small intestinal expression levels of Abcb1a and Abcg2 were not significantly different from those in wild-type mice, although experimental variation was quite substantial ( Figure 1A and B). As expected, there was no significant expression of Abcb1a and Abcg2 in the small intestine of
mice. The results suggest that, for small intestine, expression levels of Abcb1a and Abcg2 were not halved upon halving the gene copy number of the genes, but instead remained similar to the wild-type expression levels.
In contrast, Abcb1a RNA was 3.4-fold, and Abcg2 RNA 2.3-fold lower in the brain of male heterozygous mice as compared with wild-type mice, albeit with substantial variation in both wildtype and heterozygous values ( Figure 1C and D). There was no significant expression of Abcb1a
and Abcg2 in the homozygous knockout mice. In vivo brain accumulation studies have also been performed using female mice (Durmus et al., 2012) , and we now found that in female heterozygous mice, the brain expression levels of Abcb1a and Abcg2 were also about half of the levels observed in wild-type mice ( Figure 1E and F). Of note, relative expression levels of either Upon sorafenib oral administration, although there were a few significant differences at individual time points, there was no significant difference in the overall plasma AUC 0-6hr among the 3 tested strains. This suggests that Abcb1 and Abcg2 did not play a role in the overall AUC 0-6hr of sorafenib ( Figure 2B , E and Table 2 ), consistent with the data of Lagas et al. (2010) .
Heterozygous and homozygous knockout mice also showed oral sunitinib plasma AUC 0-6hr values that were not significantly different from wild-type values ( Figure 2C ), although experimental variation was substantial. Probably related to that, the plasma AUC 0-6hr of Abcb1a/1b(+/-);Abcg2(+/-) mice was 1.9-fold and significantly higher (P < 0.01) than that of Figure 2C and F, Table 3 Brain accumulations of all drugs at 6 hr were also modestly increased (1.6-to 1.9-fold) in the heterozygous strain as compared to wild-type, albeit only statistically significant (P < 0.01) for dasatinib ( intrinsic capacity to accumulate into the brain, and extent to which brain accumulation is relatively affected by Abcb1 and Abcg2, suggests that many more drugs transported by ABCB1 and/or ABCG2 will be subject to the same behavior. It is worth noting that the model will also apply to any other active drug efflux transporters present in the endothelial luminal membrane of the BBB, and can in principle, with some modification, be used for any number of these transporters.
An important feature of the models is that they explain the counterintuitive disproportionate increase in drug accumulation into the brain seen when two active BBB drug efflux transporters of a drug are simultaneously knocked out (or inhibited), relative to the situation when only one is knocked out. This turns out to be simply a consequence of the fact that the active efflux transport by each of the transporters is considerably larger than the remaining (passive, or lowly active) efflux transport at the BBB in the absence of both the efflux transporters.
Thus, the apparently "synergistic" effect of simultaneously removing the activity of both transporters on brain accumulation of a drug can be explained without postulating any direct or indirect interaction between the transporters that would somehow modulate the transport activity of each of the individual (remaining) transporters when the other is knocked out. As shown and summarized before (Agarwal et al., 2012; Durmus et al., 2012) , single homozygous knockout of Unlike the brain expression of Abcb1a and Abcg2, in the intestine heterozygosity for the encoding genes does not result in halving of the RNA levels, but rather in levels that are similar to those in the wild-type mice (compare Figure 1A- Also a number of other studies (recently reviewed in Kalvass et al., 2013) suggest that expression and/or activity of ABCB1 and ABCG2 in the blood-brain barrier is not easily induced in either rodents or humans. This is important, as marked changes in BBB expression of active efflux transporters due to drug-drug interactions might present a risk for altered susceptibility to various CNS-active drugs. The relatively stable and apparently high expression of ABCB1 and ABCG2 in the BBB observed by others and us suggests that this risk is quite limited, and unlikely to be a major concern during routine pharmacotherapy in humans.
The three TKIs we tested at the same oral dosage (10 mg/kg) showed highly divergent oral availability and brain accumulation characteristics, in both wild-type and knockout mice (Tables 1-3 ). For instance, in wild-type mice the AUC 0-6hr of sunitinib was nearly two orders of magnitude (75-fold) lower than that of sorafenib, whereas that of dasatinib was in between (16.7-fold lower than that of sorafenib). The relative AUC 0-6hr results between the drugs in the knockout strain showed a similar profile. At the same time, the relative brain accumulation (K p ) of sunitinib in wild-type mice was 117-and 82-fold higher than that of sorafenib and dasatinib, respectively.
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Again, the profile of relative results for the K p s in the knockout strain was similar, although at a ~70-fold higher absolute level. Thus, the drug with the lowest plasma levels, sunitinib, had the highest relative brain accumulation. Clearly there can be many factors that contribute to these differences between the drugs, including differential impact of drug uptake and drug efflux transporters in the various epithelial and endothelial barriers, drug-metabolizing enzymes, saturation phenomena, hydrophobicity of the drugs and other physicochemical properties that define e.g. binding to plasma and tissue proteins and lipids. Nonetheless, despite the profound differences in intrinsic properties between the three TKIs tested here, they all adhere similarly to the models of Kodaira et al. (2010) , Kalvass and Pollack (2007) and Zamek-Glisczcynski et al. The strong increase in homozygous fetuses indicates that the Abcb1a/1b transport activity in the placenta is considerably greater than any alternative remaining placental drug efflux activity. Also consistent with the models, the more modest impact of full knockout on digoxin fetal accumulation (~2.5-fold increase) was associated with a more or less intermediate (and statistically significant) ~1.6-fold increase in the heterozygous fetuses. We infer that the impact of efflux transporters on transplacental fetal accumulation of drugs can also be adequately described by the cited pharmacokinetic models, and that for saquinavir and paclitaxel Abcb1 is by far the most important drug efflux transporter limiting fetal drug accumulation.
Our results in mice confirm that a very substantial reduction of active efflux transporter activity in the blood-brain and placental barriers (>2-fold) would be needed to achieve a >2-fold increased penetration of drug substrates into brain or fetus, respectively, even if the transporters by themselves give a very high level of protection. As argued by Kalvass et al. (2013) , it is not easy to achieve this level of inhibition of ABCB1 and ABCG2 in humans with therapeutic blood levels of currently available drugs. As the principles as described here in mice undoubtedly also apply to the human blood-tissue barriers, it seems very likely that also in humans substantial changes in drug penetration into brain and fetus due to drug-drug interactions inhibiting ABCB1
and ABCG2 are unlikely to occur. Still, one should always keep in mind that there may be species-specific differences in substrate specificity and inhibitor sensitivity of ABCB1 and ABCG2, and absolute transporter expression levels in the blood-tissue barriers may differ between man and mouse. Extrapolation of these preclinical results to humans should therefore, as always, be done with caution, and carefully tested before being applied in a clinical setting.
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